APOL1介在性腎臓病の世界市場2020年-2030年

◆英語タイトル:APOL1 Mediated Kidney Disease Market Forecast, Trend Analysis & Opportunity Assessment 2020-2030
◆商品コード:FMI21MA028
◆発行会社(リサーチ会社):Future Market Insights
◆発行日:2021年3月8日
◆ページ数:95
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
Site Licence(同一拠点内共有可)USD7,500 ⇒換算¥825,000見積依頼/購入/質問フォーム
Enterprisewide(複数拠点内共有可)USD10,000 ⇒換算¥1,100,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はFuture Market Insights社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Future Market Insights社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査資料では、APOL1介在性腎臓病の世界市場を調査対象とし、エグゼクティブサマリー、市場概要、主要産業動向、市場背景、疾病疫学、パイプライン分析、治療機会分析、疾患別(慢性腎臓病、末期腎臓病)分析、地域別分析、競争分析、仮定、調査手法などを掲載しています。
・エグゼクティブサマリー
・市場概要
・主要産業動向
・市場背景
・疾病疫学
・パイプライン分析
・治療機会分析
・世界のAPOL1介在性腎臓病市場規模:疾患別(慢性腎臓病、末期腎臓病)
・世界のAPOL1介在性腎臓病市場規模:地域別
・競争分析
・仮定
・調査手法
【レポートの概要】

A recent market study published by Future Market Insights (FMI) on the market offers global industry analysis for 2015-2019 & opportunity assessment for 2020-2030. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the APOL1 Mediated Kidney Disease market, growth prospects of the market are obtained with maximum precision. The report features unique and salient factors that may make a huge impact on the development of the APOL1 Mediated Kidney Disease market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the APOL1 Mediated Kidney Disease market in the coming years. The report provides detailed information about the current and future growth prospects of the APOL1 Mediated Kidney Disease market in the most comprehensive way for better understanding of readers.

Key Segments of APOL1 Mediated Kidney Disease Market

FMI’s study on the APOL1 Mediated Kidney Disease market offers information divided into two important segments – indication and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Indication (Symptomatic Treatment)
Chronic Kidney Disease
Focal segmental glomerulosclerosis (FSGS)
Human immunodeficiency virus (HIV)-associated Nephropathy
Hypertension-associated Kidney Disease
End-Stage Kidney Disease

Region
North America (U. S.)
Europe
Middle East & Africa

Chapter 1 – Executive Summary

The report commences with the executive summary of the APOL1 Mediated Kidney Disease market report, which includes the summary of key findings and statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the APOL1 Mediated Kidney Disease market as well as the key trends impacting the market.

Chapter 2 – Market Overview

Readers can find detailed taxonomy and product definition of the APOL1 Mediated Kidney Disease market, in this chapter, which help readers understand basic information about APOL1 Mediated Kidney Disease.

Chapter 3 – Key Market Trends

This section highlights the key trends impacting the APOL1 Mediated Kidney Disease market, which will help readers understand the current trends and their impact on market growth.

Chapter 4 – Market Background

This chapter explains the key macroeconomic factors that are expected to influence the growth of the APOL1 Mediated Kidney Disease during the forecast period. The chapter also highlights the major forecast factors that will shape market growth. Besides, it provides key dynamics of the APOL1 Mediated Kidney Disease market, which include the drivers, restraints, and opportunity analysis. This chapter is expected to enable readers to understand the factors that are propelling the growth of the APOL1 Mediated Kidney Disease market, as well as those that are likely to hamper the growth of the APOL1 Mediated Kidney Disease market. The opportunity analysis for the APOL1 Mediated Kidney Disease will help readers understand the market opportunities, based on which they can plan their strategies.

Chapter 5 – Disease Epidemiology

This section provides the overview of epidemiology of the APOL1 Mediated Kidney Disease.

Chapter 6 – Pipeline Assessment

This section provides the insights on new and upcoming products within clinical pipeline.

Chapter 7 – Global APOL 1 Mediated Kidney Disease Treatment Opportunity Assessment (US$ Mn), Till 2030

This section explains the global market value analysis and forecast for the APOL1 Mediated Kidney Disease market during the forecast period.

Chapter 8 – Global APOL 1 Mediated Kidney Disease Treatment Opportunity Assessment (US$ Mn), Till 2030, By Indication

Based on indication, the APOL1 Mediated Kidney Disease market is segmented into Chronic Kidney Disease and End-Stage Kidney Disease. In this chapter, readers can find information about a detailed analysis of the market by different treatment of APOL1 Mediated Kidney Disease and their growth over the forecast period.

Chapter 9 – Global APOL 1 Mediated Kidney Disease Treatment Opportunity Assessment (US$ Mn) v, Till 2030, by Region

This chapter explains how the APOL1 Mediated Kidney Disease market will grow across various geographic regions such as North America, Europe, and the Middle East & Africa (MEA).

Chapter 10 – Competition Analysis

In this chapter, readers can find a comprehensive list of all the leading stakeholders in the APOL1 Mediated Kidney Disease market, along with detailed information about each company, including company overview, revenue shares, strategic overview, and recent company developments. Players featured in the APOL1 Mediated Kidney Disease market report include Vertex Pharmaceuticals Incorporated and Ionis Pharmaceuticals, Inc. (partnered with AstraZeneca Plc.)

Chapter 11 – Assumptions and Acronyms Used

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.

Chapter 12 – Research Methodology

This chapter helps readers understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the autoclaves market.

Sources and Primary Research Splits (%)

Industry Interactions

Key Designations

C – Level Executives
Marketing Directors
Product Managers
Business Development Officers
Production Managers
Procurement Heads
Sales Executives
Stakeholder Category

Distributors
Traders
Raw Material Suppliers
Industry Experts
Consumptions
Questions

Current Market Dynamics and Challenges
Yesteryear Trends
Market Characteristics
Market Performance and Growth Quadrants
Competition Structure and Market Structure
Strategic Growth Initiatives
Near-term and Long-term Market Growth Prospects
Market Segment Splits and Authenticity
Opinions on Market Projections and Validity of Assumptions
References Catalogue

Industry Publications
World Health Organizations (WHO)
National Institute of Health (NIH)
Factiva
Company Press Releases
Annual Reports and Investor Presentations
Research Papers
Government Websites and Publications
Company Websites,
Morningstar

【レポートの目次】

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Technology Assessment

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Product Innovation / Development Trends

3.3. KOL Verbatim

4. Market Background

4.1. Macro-Economic Factors

4.1.1. Global GDP Growth Outlook

4.1.2. Global Healthcare Outlook

4.2. Forecast Factors – Relevance & Impact

4.2.1. Disease Epidemiology

4.2.2. Research and Developmental Activities

4.2.3. Technological Advancement

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

5. Disease Epidemiology

5.1. Epidemiology By Region

5.2. Worldwide Spread of APOL1 Renal-Risk

5.3. Worldwide Disease Burden

6. Pipeline Assessment

7. Therapeutic Pathway to APOL 1 Mediated Kidney Disease

8. Global APOL 1 Mediated Kidney Disease Treatment Opportunity Assessment (US$ Mn), Upto 2030

8.1. Global APOL 1 Mediated Kidney Disease (Symptomatic Treatment) Opportunity Assessment (US$ Mn), Upto 2030

8.1.1. Future Market Forecast (US$ Mn) Projections, Upto 2030

8.1.1.1. Y-o-Y Growth Trend Analysis

8.2. Global APOL 1 Mediated Kidney Disease (Pipeline Targeted Therapeutics) Opportunity Assessment (US$ Mn), Upto 2030

8.2.1. Future Market Forecast (US$ Mn) Projections, Upto 2030

8.2.1.1. Y-o-Y Growth Trend Analysis

9. Global APOL 1 Mediated Kidney Disease Treatment Opportunity Assessment (US$ Mn), Upto 2030, By Indication

9.1. Global APOL 1 Mediated Kidney Disease (Symptomatic Treatment) Opportunity Assessment (US$ Mn), Upto 2030

9.1.1. Introduction / Key Findings

9.1.1. Future Market Forecast (US$ Mn) Projections, Upto 2030

9.1.2. Chronic Kidney Disease

9.1.2.1.1. Focal segmental glomerulosclerosis (FSGS)

9.1.2.1.2. Human immunodeficiency virus (HIV)-associated Nephropathy

9.1.2.1.3. Hypertension-associated Kidney Disease

9.1.3. End-Stage Kidney Disease

9.2. Market Attractiveness Analysis By Indication

9.3. Global APOL 1 Mediated Kidney Disease (Pipeline Targeted Therapeutics) Opportunity Assessment (US$ Mn), Upto 2030

9.3.1. Introduction / Key Findings

9.3.2. Future Market Forecast (US$ Mn) Projections, Upto 2030

9.3.3. Chronic Kidney Disease

9.3.3.1.1. Focal segmental glomerulosclerosis (FSGS)

9.3.3.1.2. Human immunodeficiency virus (HIV)-associated Nephropathy

9.3.3.1.3. Hypertension-associated Kidney Disease

9.3.4. End-Stage Kidney Disease

9.4. Market Attractiveness Analysis By Indication

10. Global APOL 1 Mediated Kidney Disease Treatment Opportunity Assessment (US$ Mn), Up to 2030, by Region

10.1. Global APOL 1 Mediated Kidney Disease (Symptomatic Treatment) Opportunity Assessment (US$ Mn) v, Up to 2030, by Region

10.1.1. Introduction / Key Findings

10.1.2. Future Market Forecast (US$ Mn) Projections, Up to 2030

10.1.3. North America

10.1.3.1. U.S.

10.1.4. Europe

10.1.5. Middle East and Africa

10.1.6. Market Attractiveness Analysis By Region

10.2. Global APOL 1 Mediated Kidney Disease (Pipeline Targeted Therapeutics) Opportunity Assessment (US$ Mn) v, up to 2030, by Region

10.2.1. Introduction / Key Findings

10.2.2. Future Market Forecast (US$ Mn) Projections, Up to 2030

10.2.3. North America

10.2.3.1. U.S.

10.3. Market Attractiveness Analysis By Region

11. Competition Analysis

11.1. Competition Landscape

11.2. Competition Deep Dive

11.2.1. Vertex Pharmaceuticals Incorporated

11.2.2. Ionis Pharmaceuticals, Inc

12. Assumptions and Acronyms Used

13. Research Methodology

Table 01: Global APOL1 Mediated Kidney Disease (Symptomatic Treatment) Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication

Table 02: Global APOL1 Mediated Kidney Disease (Pipeline Therapeutics) Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication

Table 03: Global APOL1 Mediated Kidney Disease (Symptomatic Treatment) Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Region

Table 04: Global APOL1 Mediated Kidney Disease (Pipeline Therapeutics) Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Region

Figure 01: Global APOL1 Mediated Kidney Disease Market Value Analysis (US$ Mn), 2015-2019

Figure 02: Global APOL1 Mediated Kidney Disease Market Value Forecast (US$ Mn), 2020-2030

Figure 03: Global APOL1 Mediated Kidney Disease Market Absolute $ Opportunity, 2019 - 2030

Figure 04: Global APOL1 Mediated Kidney Disease (Symptomatic Treatment) Market Share Analysis (%), By Indication, 2020 & 2030

Figure 05: Global APOL1 Mediated Kidney Disease (Symptomatic Treatment) Market Y-o-Y Analysis (%), By Indication, 2020-2030

Figure 06: Global APOL1 Mediated Kidney Disease (Symptomatic Treatment) Market Attractiveness Analysis by Indication, 2020-2030

Figure 07: Global APOL1 Mediated Kidney Disease (Pipeline Therapeutics) Market Share Analysis (%), By Indication, 2020 & 2030

Figure 08: Global APOL1 Mediated Kidney Disease (Pipeline Therapeutics) Market Y-o-Y Analysis (%), By Indication, 2020-2030

Figure 09: Global APOL1 Mediated Kidney Disease (Pipeline Therapeutics) Market Attractiveness Analysis by Indication, 2020-2030

Figure 10: Global APOL1 Mediated Kidney Disease (Symptomatic Treatment) Market Share Analysis (%), By Region, 2020 & 2030

Figure 11: Global APOL1 Mediated Kidney Disease (Symptomatic Treatment) Market Y-o-Y Analysis (%), By Region, 2020-2030

Figure 12: Global APOL1 Mediated Kidney Disease Market Attractiveness Analysis by Region, 2020-2030

Figure 13: Global APOL1 Mediated Kidney Disease (Pipeline Therapeutics) Market Share Analysis (%), By Region, 2020 & 2030

Figure 14: Global APOL1 Mediated Kidney Disease (Pipeline Therapeutics) Market Y-o-Y Analysis (%), By Region, 2020-2030

Figure 15: Global APOL1 Mediated Kidney Disease (Pipeline Therapeutics) Market Attractiveness Analysis by Region, 2020-2030

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[APOL1介在性腎臓病の世界市場2020年-2030年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆